Highlights ALK-Abelló A/S

Equities

ALK B

DK0061802139

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:46 2024-06-07 am EDT			5-day change	1st Jan Change
143.7 ^DKK	+1.55%		-5.83%	+42.00%

Jun. 04	Transcript : ALK-Abelló A/S - Analyst/Investor Day
Jun. 03	ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy	Jun. 03	CI
Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review	May. 30	CI
ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	May. 02	CI
ALK-Abelló A/S Provides Earnings Guidance for the Year 2024	May. 02	CI
New entries in MarketScreener's Europe portfolio	Mar. 04
ALK-Abelló A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024	Feb. 08	CI
Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review	Jan. 25	CI
ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet	Jan. 18	CI
ALK-Abelló Closes Purchase of US Skin Antigen Test Maker AllerQuest	Jan. 04	MT
ALK-Abelló A/S (CPSE:ALK B) acquired Business Assets of AllerQuest.	Jan. 03	CI
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12	CI
Alk-Abelló A/S Provides Earnings Guidance for the Year 2023	Nov. 15	CI
ALK-Abelló A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet	23-10-11	CI
ALK-Abelló A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023	23-08-24	CI
Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite Induced Allergic Rhinitis	23-06-08	CI
ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ALK-Abelló A/S : No allergy on the horizon

March 12, 2024 at 10:20 am EDT